These results indicate that alexithymia is associated with subjective hypersensitivity to bodily sensations. Moreover, our findings support the theoretical proposal that alexithymia is an expression of impaired processing of bodily sensations including physiological arousal, which underpin the development of maladaptive coping strategies, including alcohol use disorders. Our observations extend a growing literature emphasizing the importance of interoception and alexithymia in addiction, which can inform the development of new therapeutic strategies.
Subliminal stimuli can affect perception, decision-making, and action without being accessible to conscious awareness. Most evidence supporting this notion has been obtained in highly controlled laboratory conditions. Hence, its generalization to more realistic and ecologically valid contexts is unclear. Here, we investigate the impact of subliminal cues in an immersive navigation task using the so-called eXperience Induction Machine (XIM), a human accessible mixed-reality system. Subjects were asked to navigate through a maze at high speed. At irregular intervals, one group of subjects was exposed to subliminal aversive stimuli using the masking paradigm. We hypothesized that these stimuli would bias decision-making. Indeed, our results confirm this hypothesis and indicate that a subliminal channel of interaction exists between the user and the XIM. These results are relevant in our understanding of the bandwidth of communication that can be established between humans and their physical and social environment, thus opening up to new and powerful methods to interface humans and artefacts.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.